Current Status of Databases in Japan
|
|
|
- Gabriella Bates
- 9 years ago
- Views:
Transcription
1 Current Status of Databases in Japan Kiyoshi Kubota, MD, PhD, FISPE Department of Pharmacodpiemiology, Graduate School of Medicine, University of Tokyo NPO Drug Safety Research Japan
2 Small Databases
3 Databases in Japan Small databases (including commercially available databases) posted in the web page of Japanese Society for Pharmacoepidemiology (JSPE) Electronic Health Record (EHR)-type DB Claims data From Insurers Claims data From Pharmacies ~2million people ~1million ~0.6million ~7million
4 EHR-type DBs Merits (Some) labo-data results are available Patients covered by different-types of insurance are included Almost complete data for inpatients Demerits Source population cannot be well defined Individual hospitals have no clear catchment area in Japan not quite representative of the whole patients Follow-up (particularly long follow-up) is difficult All Japanese patients are allowed to make his/her own decision on the medical institution to visit.
5 Claims data from insurers Merits Relatively long follow-up is possible The insured can be followed unless he/she changes the insurance union (~ around job change). The records of two or more clinics/hospitals he/she uses at the same time are available. Demerits No labo-data are available not representative of the whole nation Age distribution is different from the whole population. Data are those of workers and their family
6 Claims data from pharmacies Merits Records for long period (more than 10 years) Data come from many medical institutions probably more representative as compared to other 2. Demerits Source population cannot be defined No data on diagnosis, labo results and procedures Follow-up of individual patients is difficult
7 Problems common to all DBs Linkage to the data source outside the DB is currently very difficult partly due to the lack of the Social Security Number or other identifier used in Health-Care
8 Two emerging large Databases [A] Medical Information Database* mainly for Japanese Sentinel * No formal English term is available just beginning EHR-type database MHLW Pharmaceutical and Food Safety Bureau (Safety Division) + PMDA (Pharmaceuticals and Medical devices Agency) [B] National Database (NDB) Claims database (plus some data from health screening) Health Insurance Bureau in the pilot phase for the secondary use
9 Two different bureaus for Two large DBs and [A] Medical Information Database (Japanese Sentinel) [B] National Database (NDB)
10 Medical Information Database (for Japanese Sentinel)
11 Medical Information Database (for Japanese Sentinel) By 2015, EHR-type data are collected from hospital groups in 5 area in Japan aiming database covering 10 million people PMDA
12 Medical Information Database (for Japanese Sentinel) Hospital A Data mapping of local code to standardized code may be needed Query PMDA Hospital B Data Center Data for individual patients, after deleting ID info, will be collected by data center, analyzed and then deleted for each query SS-MIX: storage of standardized information
13 Medical Information Database (for Japanese Sentinel) Merits and Demerits: the same as that for HER-type data Merits (Some) labo-data results are available Almost complete data for inpatients Demerits Source population cannot be well defined not quite representative of the whole patients Follow-up (particularly long follow-up) is difficult
14 Data in data center (Medical Information database) Data in data center will be not allowed to be linked with other data source at least for the time being. For each query, data of individual patients, after deleting ID information, are collected from individual hospitals to the data center, analyzed and then deleted. However, in the future, it may be not impossible to link the data with other data sources because the original data in each hospital have the original ID information
15 National Database (NDB) in Japan
16 National Database (NDB) First advisory committee for MHLW Guidelines for use of NDB during the pilot period ( to ) issued by the MHLW MHLW received 43 applications for the secondary use of NDB (first application) Governmental bodies Universities National cancer centers and other centers with research activity Drug companies are not allowed to make application (directly) The advisory committee approved 6 of 43 applications Second application will be received by the MHLW (only those who failed in the first application can make application)
17 NDB(1) Data of claims (from ) plus Data of the results of specific health screening Data of about 20 million subjects, 38% (i.e., selective?) of 50-million target (by law) population of of age (data on BP, serum lipid, FBS, HbA1c and smoking status) Claims data Health screening data
18 NDB(2) New data are added to the old data by using the ID which is undecodable hash New Data Old claims data hash Key from hash Old health screening data
19 NDB(3) [1] number for insured (two kinds) DOB Gender [2] Name DOB Gender 2 kinds of hash will be made to match old and new data [1] may work when family name is changed (e.g., marriage) [2] may work when moving to different insurance union (e.g., job change)
20 NDB(4) It will be very difficult or actually impossible to link ID (hash) used in NDB with ID in the data source outside NDB: i.e., Data in NDB cannot be linked with demographic data cannot be linked with disease registry cannot be validated by the original medical record as long as the current policy to use hash is maintained
21 SS-MIX may provide a key function in the future Pharmacoepi study in Japan Standard Structured Medical Information exchange Methods Inf Med. 2011;50:131-9.
22 Those in individual hospitals can use SS-MIX data in the own hospital Hospital A Hospital B Data Center SS-Mix: storage of standardized information The data in each hospital can be used with its original ID information inside the hospital. The data in SS-MIX is all standardized
23 Current status of SS-MIX storage SS-MIX storage can work when introduced to the hopital with the data in standardized format (HL7 and DICOM) About 700 large hospitals have now Hospital Information System with the data in standardized format but only a few hospitals have introduced SS- MIX storage so far. Cost is about 200 thousand USD for introducing SS- MIX storage to each hospital. not very expensive but not very cheap some incentive needed for more hospitals to introduce SS-MIX
24 SS-MIX, when introduced into hundreds of hospitals, can identify cohorts of new users of two drugs which may be compared with each other, can retrieve all drugs, labo data and diagnostic codes for those cohorts automatically, so that physicians who participate in the study in each hospital may just give information on the outcome to complete individual case report and may be an important tool in particular because the record linkage is difficult with NDB.
Asian Data Resources. October 24, 2014 8:30-12:30 Using pharmacoepidemiology database resources to address drug safety research
Draft Asian Data Resources October 24, 2014 8:30-12:30 Using pharmacoepidemiology database resources to address drug safety research Kiyoshi Kubota MD PhD FISPE NPO Drug Safety Research Unit Japan Multiple
Fujitsu Healthcare Business Overview
ITU Workshop on E-health services in low-resource settings: Requirements and ITU role (Tokyo, Japan, 4-5 February 2013) Fujitsu Healthcare Business Overview Yoshiyuki Takahashi, Director, Global / New
1/16/2015 HOW CLINICAL EDUCATORS CAN DISCLOSURE LEARNING OBJECTIVES MAKE MEANINGFUL USE MEANINGFUL. We have no financial disclosures
HOW CLINICAL EDUCATORS CAN MAKE MEANINGFUL USE MEANINGFUL Daryl Wieland, MD Tammy Gruenberg, MD Michelle Giannone, MD Albert Einstein College of Medicine, Bronx, NY DISCLOSURE We have no financial disclosures
Speaker Second Plenary Session ELECTRONIC HEALTH RECORDS FOR INFORMED HEALTH CARE IN ASIA- PACIFIC: LEARNING FROM EACH OTHER.
Speaker Second Plenary Session ELECTRONIC HEALTH RECORDS FOR INFORMED HEALTH CARE IN ASIA- PACIFIC: LEARNING FROM EACH OTHER Naoto Kume, PhD Kyoto University Kyoto Prefecture, Japan ISPOR 2014.09.08 11:15am-12:45pm
How To Improve The Pharmaceutical Industry In Japanese
Pharmaceutical business innovation through utilization of EMR Abstract The pharmaceutical industry in Japan is in a transformation phase due to the government s tightening control over healthcare expenditure
Risk Management Plan (RMP) Guidance (Draft)
Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour
Application for Accreditation of Foreign Manufacturers
Application for Accreditation of Foreign Manufacturers (This English document is only for reference purpose. In case of any discrepancy, the Japanese text shall prevail. For further information, please
Secondary Uses of Data for Comparative Effectiveness Research
Secondary Uses of Data for Comparative Effectiveness Research Paul Wallace MD Director, Center for Comparative Effectiveness Research The Lewin Group [email protected] Disclosure/Perspectives Training:
Meaningful Use Objectives
Meaningful Use Objectives The purpose of the electronic health records (EHR) incentive program is not so much the adoption of health information technology (HIT), but rather how HIT can further the goals
A method for handling multi-institutional HL7 data on Hadoop in the cloud
A method for handling multi-institutional HL7 data on Hadoop in the cloud { Masamichi Ishii *1, Yoshimasa Kawazoe *1, Akimichi Tatsukawa 2*, Kazuhiko Ohe *2 *1 Department of Planning, Information and Management,
Public Health and the Learning Health Care System Lessons from Two Distributed Networks for Public Health
Public Health and the Learning Health Care System Lessons from Two Distributed Networks for Public Health Jeffrey Brown, PhD Assistant Professor Department of Population Medicine Harvard Medical School
Meaningful Use: Stage 1 and 2 Hospitals (EH) and Providers (EP) Lindsey Mongold, MHA HIT Practice Advisor Oklahoma Foundation for Medical Quality
Meaningful Use: Stage 1 and 2 Hospitals (EH) and Providers (EP) Lindsey Mongold, MHA HIT Practice Advisor Oklahoma Foundation for Medical Quality Meaningful Use Stage 1 Focuses on Functional & Interoperability
Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009
Joint Position on the Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases 1 Updated November 10, 2009 The innovative pharmaceutical industry 2 is committed to the transparency
Environmental Health Science. Brian S. Schwartz, MD, MS
Environmental Health Science Data Streams Health Data Brian S. Schwartz, MD, MS January 10, 2013 When is a data stream not a data stream? When it is health data. EHR data = PHI of health system Data stream
Guide To Meaningful Use
Guide To Meaningful Use Volume 1 Collecting the Data Contents INTRODUCTION... 3 CORE SET... 4 1. DEMOGRAPHICS... 5 2. VITAL SIGNS... 6 3. PROBLEM LIST... 8 4. MAINTAIN ACTIVE MEDICATIONS LIST... 9 5. MEDICATION
MEANINGFUL USE STAGE 2 REQUIREMENTS FOR ELIGIBLE PROVIDERS USING CERTIFIED EMR TECHNOLOGY
MEANINGFUL USE STAGE 2 REQUIREMENTS FOR ELIGIBLE PROVIDERS USING CERTIFIED EMR TECHNOLOGY On August 24, the Centers for Medicare & Medicaid Services (CMS) posted the much anticipated final rule for Stage
Secondary Uses of Health Data IMPAC s Oncology Data Alliance Program
Secondary Uses of Health Data IMPAC s Oncology Data Alliance Program NCVHS August 1, 2007 Joel Goldwein, MD Senior Vice President, Medical Affairs IMPAC Medical Systems Inc. IMPAC Medical Systems, Inc.
Key Learnings Pharmacy Access Project. Key Learnings and Applications. Changes in Medication Adherence Rates. Jack Mahoney, MD Medical Director
Key Learnings Pharmacy Access Project Jack Mahoney, MD Medical Director Medications adherence rates in VBID group increased consistently across all study periods. 2 Changes in Medication Adherence Rates
Enabling Patients Decision Making Power: A Meaningful Use Outcome. Lindsey Mongold, MHA HIT Practice Advisor Oklahoma Foundation for Medical Quality
Enabling Patients Decision Making Power: A Meaningful Use Outcome Lindsey Mongold, MHA HIT Practice Advisor Oklahoma Foundation for Medical Quality Today 1. Meaningful Use (MU) 2. 2/3rds of MU relates
MEANINGFUL USE STAGE 2 2015 FOR ELIGIBLE PROVIDERS USING CERTIFIED EMR TECHNOLOGY
MEANINGFUL USE STAGE 2 2015 FOR ELIGIBLE PROVIDERS USING CERTIFIED EMR TECHNOLOGY STAGE 2 REQUIREMENTS EPs must meet or qualify for an exclusion to 17 core objectives EPs must meet 3 of the 6 menu measures.
Health Information Technology and the National Quality Agenda. Daphne Ayn Bascom, MD PhD Chief Clinical Systems Officer Medical Operations
Health Information Technology and the National Quality Agenda Daphne Ayn Bascom, MD PhD Chief Clinical Systems Officer Medical Operations Institute of Medicine Definition of Quality "The degree to which
Strengthening the HCV Continuum of Care
Strengthening the HCV Continuum of Care Fabienne Laraque, MD, MPH, Medical Director Viral Hepatitis Surveillance, Prevention and Control Bureau of Communicable Diseases Control, NYC DOHMH March 18, 2014
Risk Management Plan (RMP) on Biologicals and NCE
Transformation towards a New Regulatory Paradigm Risk Management Plan (RMP) on Biologicals and NCE Junko SATO International Coordination Officer PMDA, Japan 1 2 Pharmaceuticals and Medical Devices Agency
HEALTH CARE DATA IN QATAR
HEALTH CARE DATA IN QATAR Daoud Al-Badriyeh, PhD President, ISPOR Qatar Chapter and Assistant Professor of Pharmacoeconomics College of Pharmacy, Qatar University Doha, Qatar Health Care Data The problem:
gehr Project: Nation-wide EHR Implementation in JAPAN
Kyoto Smart city Expo. 2016.06.01 Kyoto University University of Miyazaki gehr Project: Nation-wide EHR Implementation in JAPAN YOSHIHARA Hiroyuki, MD/Ph.D Emeritus professor of Kyoto University and University
Meaningful Use. Medicare and Medicaid EHR Incentive Programs
Meaningful Use Medicare and Medicaid Table of Contents What is Meaningful Use?... 1 Table 1: Patient Benefits... 2 What is an EP?... 4 How are Registration and Attestation Being Handled?... 5 What are
ELECTRONIC MEDICAL RECORDS (EMR)
ELECTRONIC MEDICAL RECORDS (EMR) SAUDI BOARD FOR COMMUNITY MEDICINE FIRST PART - FIRST SEMESTER (FALL 2010) COURSE SBCM 002: MEDICAL INFORMATICS Osama Alswailem MD MA Medical Record function 1. It s a
Information for patients and the public and patient information about DNA / Biobanking across Europe
Information for patients and the public and patient information about DNA / Biobanking across Europe BIOBANKING / DNA BANKING SUMMARY: A biobank is a store of human biological material, used for the purposes
Electronic Medical Records
Electronic Medical Records Milisa K Rizer, MD, MPH Clinical Director, Integrated Healthcare Information System Associate Professor, Clinical Family Medicine The Ohio State University Medical Center 2011
Manitoba EMR Data Extract Specifications
MANITOBA HEALTH Manitoba Data Specifications Version 1 Updated: August 14, 2013 1 Introduction The purpose of this document 1 is to describe the data to be included in the Manitoba Data, including the
MICROMD EMR VERSION 9.0 2014 OBJECTIVE MEASURE CALCULATIONS
MICROMD EMR VERSION 9.0 2014 OBJECTIVE MEASURE CALCULATIONS TABLE OF CONTENTS PREFACE Welcome to MicroMD EMR... i How This Guide is Organized... i Understanding Typographical Conventions... i Cross-References...
Electronic Health Records - An Overview - Martin C. Were, MD MS March 24, 2010
Electronic Health Records - An Overview - Martin C. Were, MD MS March 24, 2010 Why Electronic Health Records (EHRs) EHRs vs. Paper Components of EHRs Characteristics of a good EHRs A Kenyan EHRs implementation
Electronic health records to study population health: opportunities and challenges
Electronic health records to study population health: opportunities and challenges Caroline A. Thompson, PhD, MPH Assistant Professor of Epidemiology San Diego State University [email protected]
Custom Report Data Elements: IT Database Fields. Source: American Hospital Association IT Survey
Custom Report Data Elements: IT Database Fields Source: American Hospital Association IT Survey TABLE OF CONTENTS COMPUTERIZED SYSTEM IMPLEMENTATION... 4 Bar Coding... 4 Computerized Provider Order Entry...
Meaningful Use of Certified EHR Technology with My Vision Express*
Insight Software, LLC 3050 Universal Blvd Ste 120 Weston FL 33331-3528 Tel. 877-882-7456 www.myvisionexpress.com Meaningful Use of Certified EHR Technology with My Vision Express* Eligible Professional
IMS Meaningful Use Webinar
IMS Meaningful Use Webinar Presented on: May 9 11:00am 12:00pm (PDT) May 13 12:00pm 1:00pm (EST) This Webinar Will Be Recorded! Please send questions that you may have after the session to: [email protected]
CRITICAL ILLNESS CLAIM FORM
CRITICAL ILLNESS CLAIM FORM Critical Illness Claim Form - Instructions Policyholder (employer or plan administrator) Please complete the Policyholder s Statement and ensure that you answer each question
Meaningful Use: Registration, Attestation, Workflow Tips and Tricks
Meaningful Use: Registration, Attestation, Workflow Tips and Tricks Allison L. Weathers, MD Medical Director, Information Services Rush University Medical Center Gregory J. Esper, MD, MBA Vice Chair, Neurology
STAGES 1 AND 2 REQUIREMENTS FOR MEETING MEANINGFUL USE OF EHRs 1
STAGES 1 AND 2 REQUIREMENTS FOR MEETING MEANINGFUL USE OF EHRs 1 Requirement CPOE Use CPOE for medication orders directly entered by any licensed health care professional who can enter orders into the
Use of routinely collected electronic healthcare data: Lessons Learned
Use of routinely collected electronic healthcare data: Lessons Learned Massoud Toussi, MD, PhD, MBA European lead, Pharmacoepidemiology and Safety Real World Evidence Solutions, IMS Health, France ENCePP
Risk Adjustment: Implications for Community Health Centers
Risk Adjustment: Implications for Community Health Centers Todd Gilmer, PhD Division of Health Policy Department of Family and Preventive Medicine University of California, San Diego Overview Program and
Current Status and Problems of Breast Cancer Screening
Research and Reviews Current Status and Problems of Breast Cancer Screening JMAJ 52(1): 45 49, 2009 Noriaki OHUCHI,* 1,2 Akihiko SUZUKI,* 1,3 Yuu SAKURAI,* 1,4 Masaaki KAWAI,* 1 Yoko NARIKAWA,* 1 Hiroto
Meaningful Use Rules Proposed for Electronic Health Record Incentives Under HITECH Act By: Cherilyn G. Murer, JD, CRA
Meaningful Use Rules Proposed for Electronic Health Record Incentives Under HITECH Act By: Cherilyn G. Murer, JD, CRA Introduction On December 30, 2009, The Centers for Medicare & Medicaid Services (CMS)
CONSENT FOR MEDICAL TREATMENT
CONSENT FOR MEDICAL TREATMENT Patient Name DOB Date I, the patient or authorized representative, consent to any examination, evaluation and treatment regarding any illness, injury or other health concern
HL7 & Meaningful Use. Charles Jaffe, MD, PhD CEO Health Level Seven International. HIMSS 11 Orlando February 23, 2011
HL7 & Meaningful Use Charles Jaffe, MD, PhD CEO Health Level Seven International HIMSS 11 Orlando February 23, 2011 Overview Overview of Meaningful Use HIT Standards and Meaningful Use Overview HL7 Standards
Stage 2 Meaningful Use What the Future Holds. Lindsey Wiley, MHA HIT Manager Oklahoma Foundation for Medical Quality
Stage 2 Meaningful Use What the Future Holds Lindsey Wiley, MHA HIT Manager Oklahoma Foundation for Medical Quality An Important Reminder For audio, you must use your phone: Step 1: Call (866) 906-0123.
Population Health Management A Key Addition to Your Electronic Health Record
Population Health Management A Key Addition to Your Electronic Health Record Rosemarie Nelson, MS Principal Consultant, MGMA Sponsored by: 1 Contents Introduction... 3 Managing Populations of Patients...
Agenda. What is Meaningful Use? Stage 2 - Meaningful Use Core Set. Stage 2 - Menu Set. Clinical Quality Measures (CQM) Clinical Considerations
AQAF Health Information Technology Forum Meaningful Use Stage 2 Clinical Considerations Marla Clinkscales & Mike Bice Alabama Regional Extension Center (ALREC) August 13, 2013 0 Agenda What is Meaningful
VIII. Dentist Crosswalk
Page 27 VIII. Dentist Crosswalk Overview The final rule on meaningful use requires that an Eligible Professional (EP) report on both clinical quality measures and functional objectives and measures. While
EHR Meaningful Use Incentives for School-Based Health Clinics
EHR Meaningful Use Incentives for School-Based Health Clinics Denise Holmes Institute for Health Care Studies Michigan State University September 27, 2011 Background The Health Information Technology for
Webinar #1 Meaningful Use: Stage 1 & 2 Comparison CPS 12 & UDS 2013
New York State-Health Centered Controlled Network (NYS HCCN) Webinar #1 Meaningful Use: Stage 1 & 2 Comparison CPS 12 & UDS 2013 January 31, 2014 Ekem Merchant-Bleiberg, Director of Implementation Services
The Japan Generic Market Drivers and Obstacles for Change. Matt Heimerdinger Anterio Inc.
The Japan Generic Market Drivers and Obstacles for Change Matt Heimerdinger Anterio Inc. Quick country overview Osaka Tokyo Population: 127,520,000 Life expectancy: Male: 79.9; Female: 86.4 Pharmaceutical
THE EYE INSTITUTE. Dear Patient:
THE EYE INSTITUTE Eye Associates of Wayne P.A. 968 Hamburg Turnpike Wayne, NJ 07470 p. 973-696-0300 f. 973-696-0464 Eye Institute North, LLC 5677 Berkshire Valley Rd. Oak Ridge, NJ 07438 p. 973-208-0600
Custom Report Data Elements: 2012 IT Database Fields. Source: American Hospital Association IT Survey
Custom Report Data Elements: 2012 IT Database Fields Source: American Hospital Association IT Survey COMPUTERIZED SYSTEM IMPLEMENTATION 3 Bar Coding 3 Computerized Provider Order Entry 3 Decision Support
Disclosures. Real World Data Sources
Disclosures Real World Data Sources Christopher M. Blanchette, PhD, MBA Director, HEOR, Otsuka America Pharmaceutical Inc. Research Associate Professor, Public Health Sciences, University of North Carolina,
Using the Taiwan National Health Insurance Database to Design No Claim Discount in Hospitalization
Using the Taiwan National Health Insurance Database to Design No Claim Discount in Hospitalization Eleventh International Longevity Risk and Capital Markets Solutions Conference Sep 8, 2015 Hsin Chung
Taking Part in Research at University Hospitals Birmingham
University Hospitals Birmingham NHS Foundation Trust The Trust provides free monthly health talks on a variety of medical conditions and treatments. For more information visit www.uhb.nhs.uk or call 0121
A Greater Understanding. A Practical Guide to Clinical Trials
A Greater Understanding A Practical Guide to Clinical Trials Solving Insurance and Healthcare AccessProblems I since 1996 A Greater Understanding Patient Advocate Foundation MISSION STATEMENT Patient Advocate
The global classroom: Training the world s healthcare professionals
The global classroom: Training the world s healthcare professionals Dr Stuart Anderson Associate Dean of Studies London School of Hygiene and Tropical Medicine 1 Overview Describe the main education and
I-STOP: What You Need to Know. Lyuba Konopasek, MD Designated Institutional Official NewYork-Presbyterian Hospital August 26, 2013
I-STOP: What You Need to Know Lyuba Konopasek, MD Designated Institutional Official NewYork-Presbyterian Hospital August 26, 2013 What is I-STOP? Objectives Why is I-STOP necessary and how is it relevant
Integrated Healthcare Information System. Darko Gvozdanović, M.Sc.E.E. Department manager e-health
Integrated Healthcare Information System Darko Gvozdanović, M.Sc.E.E. Department manager e-health Agenda Healthcare challenges Ericsson addressing the challenges Integrated Healthcare Information System
How Big Data is Shaping Health Care Decisions Pat Keran Sr. Director of Innovation Optum Technologies
How Big Data is Shaping Health Care Decisions Pat Keran Sr. Director of Innovation Optum Technologies Cancer is second only to heart disease as the most common cause of death in the U.S. Thanks By 2030,
Tuberculosis Treatment in Japan: Problems and perspectives
From the Japanese Association of Medical Sciences The Japanese Society for Tuberculosis Tuberculosis Treatment in Japan: Problems and perspectives How to expand the Japanese version of DOTS JMAJ 52(2):
Disease Prevention to Reduce New Hampshire Healthcare Claims and Costs: A Data Mining Approach
Disease Prevention to Reduce New Hampshire Healthcare Claims and Costs: A Data Mining Approach Disease Prevention to Reduce New Hampshire Healthcare Claims and Costs: A Data Mining Approach Rakesh Karn,
Natalia Olchanski, MS, Paige Lin, PhD, Aaron Winn, MPP. Center for Evaluation of Value and Risk in Health, Tufts Medical Center.
ISPOR 2013, New Orleans, LA Using EMR data for conducting retrospective studies: Opportunities and Pitfalls Natalia Olchanski, MS, Paige Lin, PhD, Aaron Winn, MPP Center for Evaluation of Value and Risk
3/11/15. COPD Disease Management Tackling the Transition. Objectives. Describe the multidisciplinary approach to inpatient care for COPD patients
Faculty Disclosures COPD Disease Management Tackling the Transition Dr. Cappelluti has no actual or potential conflicts of interest associated with this presentation. Jane Reardon has no actual or potential
Treatment of Low Risk MDS. Overview. Myelodysplastic Syndromes (MDS)
Overview Amy Davidoff, Ph.D., M.S. Associate Professor Pharmaceutical Health Services Research Department, Peter Lamy Center on Drug Therapy and Aging University of Maryland School of Pharmacy Clinical
Safety Risk Management Company Perspective
Safety Risk Management Company Perspective Akihisa Harada, MD, Ph.D VP, Development Japan Pfizer Japan Inc. R&D Head Club Agenda REMS in FDAAA Safety Risk Management throughout a Drug s Lifecycle Risk
Maximizing Limited Care Management Resources to Improve Clinical Quality and Ensure Safe Transitions
Maximizing Limited Care Management Resources to Improve Clinical Quality and Ensure Safe Transitions Scott Flinn MD Deborah Schutz RN JD Fritz Steen RN Arch Health Partners A medical foundation formed
Image Retention in the PACS Era
Image Retention in the PACS Era Susan D. John, M.D. Professor and Chair, Dept. of Diagnostic and Interventional Imaging SCARD Fall 2015 Objectives At the end of this presentation, the attendee will be
Big Data Analytics in Healthcare In pursuit of the Triple Aim with Analytics. David Wiggin, Director, Industry Marketing, Teradata 20 November, 2014
Big Data Analytics in Healthcare In pursuit of the Triple Aim with Analytics David Wiggin, Director, Industry Marketing, Teradata 20 November, 2014 Agenda The Triple Aim Population Health in Russia The
Survey of Medical Care Activities in Public Health Insurance
Survey of Medical Care Activities in Public Health Insurance Outline of Survey 1 Objective This survey is to perceive the situation of medical treatment, diseases and injuries, dispensing, and use of drugs
